JP2009538897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538897A5 JP2009538897A5 JP2009512682A JP2009512682A JP2009538897A5 JP 2009538897 A5 JP2009538897 A5 JP 2009538897A5 JP 2009512682 A JP2009512682 A JP 2009512682A JP 2009512682 A JP2009512682 A JP 2009512682A JP 2009538897 A5 JP2009538897 A5 JP 2009538897A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- tautomer
- acceptable salt
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0610670.2 | 2006-05-31 | ||
| GB0610670A GB0610670D0 (en) | 2006-05-31 | 2006-05-31 | Therapeutic compounds |
| GB0707359.6 | 2007-04-17 | ||
| GB0707359A GB0707359D0 (en) | 2007-04-17 | 2007-04-17 | Therapeutic compounds |
| PCT/GB2007/050300 WO2007138355A1 (en) | 2006-05-31 | 2007-05-29 | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538897A JP2009538897A (ja) | 2009-11-12 |
| JP2009538897A5 true JP2009538897A5 (https=) | 2010-07-22 |
| JP5271897B2 JP5271897B2 (ja) | 2013-08-21 |
Family
ID=38377212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512682A Expired - Fee Related JP5271897B2 (ja) | 2006-05-31 | 2007-05-29 | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7834015B2 (https=) |
| EP (1) | EP2032140A1 (https=) |
| JP (1) | JP5271897B2 (https=) |
| AU (1) | AU2007266840B2 (https=) |
| CA (1) | CA2652167A1 (https=) |
| WO (1) | WO2007138355A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| CA2672860C (en) * | 2006-12-28 | 2013-01-29 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) * | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0907515D0 (en) * | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| US8450320B2 (en) * | 2010-04-16 | 2013-05-28 | Abbvie Inc. | Pyrrolopyrazinone inhibitors of kinases |
| JP5699223B2 (ja) * | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CA2868620C (en) * | 2012-03-28 | 2020-02-25 | Dieter Dorsch | Bicyclic pyrazinone derivatives |
| EP2864330A1 (en) * | 2012-06-20 | 2015-04-29 | F. Hoffmann-La Roche AG | Pyrrolopyrazone inhibitors of tankyrase |
| ES2753386T3 (es) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CN106573001B (zh) * | 2014-07-07 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 |
| US9994570B2 (en) | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| CN106939002B (zh) * | 2016-01-05 | 2019-09-24 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
| RU2728827C2 (ru) * | 2016-01-05 | 2020-07-31 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения |
| CN105646497B (zh) * | 2016-02-01 | 2019-06-04 | 南京格亚医药科技有限公司 | 吡咯并三嗪酮衍生物 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| EP4065099A4 (en) | 2019-11-25 | 2023-11-29 | The Research Foundation for The State University of New York | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANS FOR THE TREATMENT OF CANCER |
| AU2020444056A1 (en) | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
| JP7626783B2 (ja) | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| WO2024046420A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| WO2002090334A1 (en) | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2003211381B9 (en) * | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US20050228007A1 (en) | 2004-02-26 | 2005-10-13 | Prakash Jagtap | Isoquinoline derivatives and methods of use thereof |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| GB0615809D0 (en) | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US8299080B2 (en) | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| CA2672860C (en) * | 2006-12-28 | 2013-01-29 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
-
2007
- 2007-05-29 WO PCT/GB2007/050300 patent/WO2007138355A1/en not_active Ceased
- 2007-05-29 EP EP07733721A patent/EP2032140A1/en not_active Withdrawn
- 2007-05-29 AU AU2007266840A patent/AU2007266840B2/en not_active Ceased
- 2007-05-29 US US12/227,501 patent/US7834015B2/en not_active Expired - Fee Related
- 2007-05-29 CA CA002652167A patent/CA2652167A1/en not_active Abandoned
- 2007-05-29 JP JP2009512682A patent/JP5271897B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538897A5 (https=) | ||
| JP2010536842A5 (https=) | ||
| JP2009526830A5 (https=) | ||
| JP2011513475A5 (https=) | ||
| JP2012528166A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2009532452A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2010527373A5 (https=) | ||
| JP2019517487A5 (https=) | ||
| JP2011520906A5 (https=) | ||
| JP2012523457A5 (https=) | ||
| JP2016517417A5 (https=) | ||
| JP2013531029A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2011521911A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| JP2017537949A5 (https=) | ||
| JP2008513516A5 (https=) | ||
| WO2006101521A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| JP2009536620A5 (https=) | ||
| JP2013510123A5 (https=) | ||
| JP2017532360A5 (https=) |